Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1982 2
1983 1
1984 5
1985 8
1986 10
1987 12
1988 10
1989 15
1990 24
1991 21
1992 27
1993 29
1994 21
1995 32
1996 24
1997 24
1998 21
1999 37
2000 31
2001 32
2002 38
2003 36
2004 36
2005 37
2006 29
2007 23
2008 28
2009 31
2010 25
2011 28
2012 21
2013 21
2014 31
2015 35
2016 31
2017 26
2018 29
2019 35
2020 36
2021 21
2022 25
2023 18
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

972 results

Results by year

Filters applied: . Clear all
Page 1
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EGE; RECIST working group. Seymour L, et al. Among authors: de vries ege. Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2. Lancet Oncol. 2017. PMID: 28271869 Free PMC article. Review.
Everolimus for advanced pancreatic neuroendocrine tumors.
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Yao JC, et al. Among authors: de vries eg. N Engl J Med. 2011 Feb 10;364(6):514-23. doi: 10.1056/NEJMoa1009290. N Engl J Med. 2011. PMID: 21306238 Free PMC article. Clinical Trial.
Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.
Lee KA, Thomas AM, Bolte LA, Björk JR, de Ruijter LK, Armanini F, Asnicar F, Blanco-Miguez A, Board R, Calbet-Llopart N, Derosa L, Dhomen N, Brooks K, Harland M, Harries M, Leeming ER, Lorigan P, Manghi P, Marais R, Newton-Bishop J, Nezi L, Pinto F, Potrony M, Puig S, Serra-Bellver P, Shaw HM, Tamburini S, Valpione S, Vijay A, Waldron L, Zitvogel L, Zolfo M, de Vries EGE, Nathan P, Fehrmann RSN, Bataille V, Hospers GAP, Spector TD, Weersma RK, Segata N. Lee KA, et al. Among authors: de vries ege. Nat Med. 2022 Mar;28(3):535-544. doi: 10.1038/s41591-022-01695-5. Epub 2022 Feb 28. Nat Med. 2022. PMID: 35228751 Free PMC article.
Visualizing Cancer.
Krummel M, Hu K, de Vries EGE, Goetz JG, Passaro D, Subramaniam S, Misteli T, Skala M, Bravo-Cordero JJ, Sutcliffe JL. Krummel M, et al. Among authors: de vries ege. Cancer Cell. 2020 Dec 14;38(6):753-756. doi: 10.1016/j.ccell.2020.11.014. Cancer Cell. 2020. PMID: 33321083 Free article.
When is off-label off-road?
de Vries EGE, Cherny NI, Voest EE. de Vries EGE, et al. Ann Oncol. 2019 Oct 1;30(10):1536-1538. doi: 10.1093/annonc/mdz445. Ann Oncol. 2019. PMID: 31688929 Free PMC article. No abstract available.
Perspectives on imaging and immunotherapy: a review series.
de Vries EG, Schwartz LH. de Vries EG, et al. J Immunother Cancer. 2022 Jun;10(6):e005006. doi: 10.1136/jitc-2022-005006. J Immunother Cancer. 2022. PMID: 35710295 Free PMC article. No abstract available.
Molecular imaging to support cancer immunotherapy.
van de Donk PP, Oosting SF, Knapen DG, van der Wekken AJ, Brouwers AH, Lub-de Hooge MN, de Groot DA, de Vries EG. van de Donk PP, et al. Among authors: de vries eg. J Immunother Cancer. 2022 Aug;10(8):e004949. doi: 10.1136/jitc-2022-004949. J Immunother Cancer. 2022. PMID: 35922089 Free PMC article. Review.
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE, Rottey S, Geenen J, Eskens F, Gil-Martin M, Mommers EC, Koper NP, Aftimos P. Banerji U, et al. Among authors: de vries ege. Lancet Oncol. 2019 Aug;20(8):1124-1135. doi: 10.1016/S1470-2045(19)30328-6. Epub 2019 Jun 27. Lancet Oncol. 2019. PMID: 31257177 Free article. Clinical Trial.
Molecular Imaging in Cancer Drug Development.
Waaijer SJH, Kok IC, Eisses B, Schröder CP, Jalving M, Brouwers AH, Lub-de Hooge MN, de Vries EGE. Waaijer SJH, et al. Among authors: de vries ege. J Nucl Med. 2018 May;59(5):726-732. doi: 10.2967/jnumed.116.188045. Epub 2018 Jan 25. J Nucl Med. 2018. PMID: 29371402 Free article. Review.
972 results